Finanzen von Immunitybio Inc (IBRX)IBRXImmunitybio Inc

Evaluating the bottom line, ImmunityBio, Inc. maintains a gross margin of 99.42%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -120.41%, while the net margin is -449.63%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively IBRX converts its operational activities into shareholder value.

In the context of the broader market, IBRX competes directly with industry leaders such as MDGL and CYTK. With a market capitalization of $11.14B, it holds a leading position in the sector. When comparing efficiency, IBRX's gross margin of 99.42% stands against MDGL's 89.02% and CYTK's 80.46%. Such benchmarking helps identify whether ImmunityBio, Inc. is trading at a premium or discount relative to its financial performance.

ImmunityBio's revenue has shown significant growth, with Q2 2026 revenue at $51,240,000, up from $7,552,000 in Q4 2024. However, net income remains negative, with Q2 2026 at -$230,378,000, indicating ongoing financial challenges.